- Home
- QDEL vs KBDC Comparison
QDEL vs KBDC Comparison
Compare QDEL & KBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | QDEL | KBDC |
|---|---|---|
| Founded | 1979 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 918.9M |
| IPO Year | 2022 | 2018 |
Fundamental Metrics
Financial Performance| Metric | QDEL | KBDC |
|---|---|---|
| Price | $17.32 | $14.50 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $28.25 | $15.40 |
| AVG Volume (30 Days) | ★ 1.9M | 279.3K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 13.33% |
| EPS Growth | ★ 45.35 | N/A |
| EPS | N/A | ★ 1.67 |
| Revenue | ★ $2,730,200,000.00 | N/A |
| Revenue This Year | $3.51 | $193.84 |
| Revenue Next Year | $3.86 | $9.00 |
| P/E Ratio | ★ N/A | $8.54 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.70 | $13.06 |
| 52 Week High | $37.24 | $16.40 |
Technical Indicators
Market Signals| Indicator | QDEL | KBDC |
|---|---|---|
| Relative Strength Index (RSI) | 49.52 | 64.59 |
| Support Level | $14.45 | $14.07 |
| Resistance Level | $17.55 | $15.08 |
| Average True Range (ATR) | 1.24 | 0.32 |
| MACD | 0.37 | 0.07 |
| Stochastic Oscillator | 89.61 | 93.03 |
Price Performance
Historical ComparisonAbout QDEL QuidelOrtho Corporation
QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.
About KBDC Kayne Anderson BDC Inc.
Kayne Anderson BDC Inc is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company, investing mainly in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation mainly through debt investments in middle-market companies.